Everyday moments **AND** *ROS1+ lung cancer* **CAN COEXIST**

JIDEYTRO (pronounced jih-DAY-troh) is a new treatment designed to target your advanced *ROS1*+ non-small cell lung cancer (NSCLC).

ROS1+=ROS proto-oncogene 1-positive.

Patient portrayal.

What is JIDEYTRO™ (zidesamtinib)?

JIDEYTRO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:

- has spread within the chest or other parts of the body and is caused by an abnormal ROS1 gene, and
- who have received a ROS1 kinase inhibitor.

It is not known if JIDEYTRO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

JIDEYTRO can cause serious side effects, including:

- **Central nervous system (CNS) effects.** Tell your healthcare provider right away if you or your family member taking JIDEYTRO develop any new or worsening CNS symptoms during treatment, including:
  - dizziness
  - fainting
  - walking, balance, or coordination problems
  - forgetfulness, confusion, attention or thinking problems
  - speaking problems
  - seizures
  - mood or personality changes, including anxiety, irritability
  - depression, including thoughts of suicide or dying
  - seeing or hearing things that are not real (hallucinations)

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets

What does treatment on your terms look like?

Exploring treatment with

Jideytro™
(zidesamtinib) | 25 mg 100 mg tablets

Patient portrayal.

What should I look for in a treatment? ____ 3
Designed for the *ROS1*+ community ____ 4
How was JIDEYTRO studied? ____ 5
Clinical study results with JIDEYTRO after:
1 to 4 prior ROS1-targeted therapies ____ 8
Only 1 prior ROS1-targeted therapy ____ 11
Important Safety Information ____ 12
Safety and side effects ____ 16
How should I take JIDEYTRO? ____ 18
Nuvalent Patient Support ____ 19
Your *ROS1*+ NSCLC community ____ 21

IMPORTANT SAFETY INFORMATION (cont.)

JIDEYTRO can cause serious side effects, including: (cont.)

- **Changes in the electrical activity of your heart called QT prolongation.** QT prolongation can cause irregular heartbeats that can be life-threatening or cause sudden death. Your healthcare provider will do tests before and during your treatment with JIDEYTRO to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with JIDEYTRO.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

What to look for in a *ROS1*+ NSCLC treatment

An effective, targeted therapy that addresses the challenges of your disease is important

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

Consider your treatment goals when evaluating therapy options and when discussing a care plan with your doctor.

Things to consider:

Does the treatment target *ROS1* and shrink cancer if it has spread to the brain or elsewhere in the body?

Has the treatment been shown to work for people who already received prior ROS1-targeted therapies?

Is the treatment tolerable, and can you manage side effects throughout the course of therapy?

NSCLC=non-small cell lung cancer.

IMPORTANT SAFETY INFORMATION (cont.)

JIDEYTRO can cause serious side effects, including: (cont.)

- **Lung problems.** JIDEYTRO can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough (with or without mucus), or fever.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

JIDEYTRO was designed for people whose NSCLC is *ROS1+*

Created with you in mind

Nuvalent's mission is to make a difference for people living with cancer through new medicines created with their unique disease in mind. JIDEYTRO was designed for people whose NSCLC is *ROS1+*

Designed and developed in collaboration with the *ROS1+* community

Nuvalent partnered with leading ROS1-focused oncologists, scientific advisors, and patient advocacy groups to understand the experiences and medical challenges faced by real people with *ROS1+* NSCLC. These learnings shaped the design goals of JIDEYTRO and its clinical study



Intended to be inclusive

JIDEYTRO was designed with the different treatment experiences of real people with *ROS1+* NSCLC in mind. Its clinical study included people who had taken 1 prior ROS1-targeted therapy and those who had tried multiple prior therapies, people with and without brain metastases, and people with and without secondary *ROS1* resistance mutations

IMPORTANT SAFETY INFORMATION (cont.)

JIDEYTRO can cause serious side effects, including: (cont.)

- **Bone fractures.** JIDEYTRO can increase your risk of bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

How was JIDEYTRO studied?

A clinical study was run to determine 3 key results:

1. The number of people whose cancer responded*
2. How long the treatment continued to work
3. What side effects people experienced

*This was the primary goal of the clinical study.

IMPORTANT SAFETY INFORMATION (cont.)

JIDEYTRO can cause serious side effects, including: (cont.)

- **Muscle pain, tenderness, and weakness (myalgia).** JIDEYTRO can cause myalgia with an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your CPK blood levels every 2 weeks during the first month, then every 1 to 2 months and as needed if you get unexplained muscle pain, tenderness, or weakness during your treatment with JIDEYTRO. Tell your healthcare provider if you develop any of these symptoms.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

The study looked at how JIDEYTRO may help people with various treatment experiences in *ROS1*+ NSCLC

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

There was a wide range in the number of prior therapies people had received and in which therapies they had received

The clinical benefit of JIDEYTRO was studied in 117 people who were already treated with 1 to 4 ROS1-targeted therapies for advanced *ROS1*+ NSCLC.

50%
of people had received **1 prior ROS1-targeted therapy before JIDEYTRO**

50%
of people were heavily pretreated **(2 or more ROS1-targeted therapies before JIDEYTRO)**

Previous ROS1-targeted therapies included:

- crizotinib
- entrectinib
- lorlatinib
- repotrectinib
- taletrectinib

52% (61 out of 117) had also received prior chemotherapy.

The study included people with two known treatment challenges in *ROS1*+ NSCLC:

49%
(57 out of 117) had **brain metastases** (cancer that has spread to the brain)

36%
(42 out of 117) had ***ROS1* resistance mutations** (changes in cancer that make it harder for treatment to keep working)

IMPORTANT SAFETY INFORMATION (cont.)

JIDEYTRO can cause serious side effects, including: (cont.)

- **Inflammation of the pancreas (pancreatitis).** JIDEYTRO may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider will do blood tests to check your pancreatic enzyme blood levels during treatment with JIDEYTRO. Tell your healthcare provider right away if you get any signs and symptoms of pancreatitis, including upper stomach (abdominal) pain that may spread to the back and get worse with eating, weight loss, or nausea.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Patient portrayal.

How were clinical benefits **measured?**

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

Overall response rate (ORR): The proportion of people who saw their tumors shrink by at least 30%* or disappear during treatment and follow-up in the clinical study. This includes both **partial response** and **complete response**.



Partial response (PR): The cancer has shrunk by at least 30%,* and there are no signs the cancer has grown anywhere else in the body

Complete response (CR): When signs of a tumor have completely disappeared with no evidence of disease visible on scans or other tests. This does not mean the cancer has been cured

Duration of response (DOR): The length of time that a person keeps living without their cancer progressing, after seeing a **complete response** or **partial response.**



*At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.

IMPORTANT SAFETY INFORMATION (cont.)

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you:

- have nervous system (neurological) or psychiatric problems.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Long-lasting results for people* who previously received 1 to 4 prior ROS1-targeted therapies, including those who were heavily pretreated

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets



43.1%
(50 out of 117) had their tumors **shrink**† (partial response)

0.9%
(1 out of 117) had their tumors **disappear**‡ (complete response)

Duration of response (DOR):

69% of people who responded to treatment **(35 out of 51)** had results that lasted at least **12 months**

The **longest DOR** observed in the clinical study with JIDEYTRO was **28.5 months** (the DOR ranged from 1.9 to 28.5+ months). At the time of the last study follow-up, the person was still responding to JIDEYTRO

Because participants had already tried between 1 and 4 ROS1-targeted therapies before JIDEYTRO, the results reflect how the therapy performed in people with advanced treatment histories

Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.

*"Long-lasting results" is based on the overall response rate and the 12-month duration of response rate in the full study population.
†At least a 30% decrease as measured by RECIST during 2 different tumor evaluations.
‡A complete response (tumor disappearing) does not mean the cancer has been cured.

IMPORTANT SAFETY INFORMATION (cont.)

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you: (cont.)

- have heart problems, including a condition called long QT syndrome.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Shown to work against disease that had spread to the brain*

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets

For people who had received 1 to 4 prior ROS1-targeted therapies



26%
(13 out of 50) had their **brain tumors shrink†** (intracranial partial response)

22%
(11 out of 50) had their **brain tumors disappear‡** (intracranial complete response)

Intracranial (in the brain) duration of response:

63% of people who responded
to treatment **(15 out of 24)** had results that lasted at least **12 months**

Limitations of exploratory findings

Some study results, including the results above, are called exploratory. Exploratory findings look at additional questions beyond the main study goals. Because the results are from a small number of people, they should be interpreted carefully. These results may not reflect everyone's experience

Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.

*These people had measurable brain tumors when the clinical study began and had not received radiation therapy to the brain within 2 months prior to study entry.

†At least a 30% decrease as measured by RECIST during 2 different tumor evaluations.

‡A complete response (tumor disappearing) does not mean the cancer has been cured.

IMPORTANT SAFETY INFORMATION (cont.)

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you: (cont.)

- have lung or breathing problems other than lung cancer.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

JIDEYTRO worked when *ROS1*+ NSCLC stopped responding to other treatments due to *ROS1* resistance mutations

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets

Resistance mutations are genetic changes in tumor cells that cause certain treatments to be less effective. They can be detected through repeat biomarker testing during or following treatment.

For people who had received 1 to 3 prior ROS1-targeted therapies and who had *ROS1* resistance mutations

Overall response rate:

50%

(21 out of 42 people) had their tumors **shrink* or disappear**† with JIDEYTRO

People in the study who saw benefit from JIDEYTRO included those who **had a variety of *ROS1* resistance mutations, including *G2032R*** (the most common resistance mutation in *ROS1*+ NSCLC), *G2032K*, *D2033N*, *F2004C/V*, and *G1957A*.

Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.

*At least a 30% decrease as measured by RECIST during 2 different tumor evaluations.
†A complete response (tumor disappearing) does not mean the cancer has been cured.

IMPORTANT SAFETY INFORMATION (cont.)

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you: (cont.)

- are pregnant or plan to become pregnant. JIDEYTRO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JIDEYTRO.

  Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with JIDEYTRO. Use effective birth control (contraception) during treatment and for 6 months after the last dose of JIDEYTRO. Talk to your healthcare provider about birth control methods that may be right for you.

  Males with a female partner who are able to become pregnant: Use effective birth control during treatment and for 3 months after the last dose of JIDEYTRO.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Results for people who had previously received only 1 prior ROS1-targeted therapy

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets

For people whose second therapy was JIDEYTRO



Duration of response:

86% of people who responded

to treatment **(25 out of 29)** had results that lasted at least **12 months**

Limitations of exploratory findings

Some study results, including the results above, are called exploratory. Exploratory findings look at additional questions beyond the main study goals. Because the results are from a small number of people, they should be interpreted carefully. These results may not reflect everyone's experience

Of the 117 people in the study, half (50%) had received 1 prior ROS1-targeted therapy (crizotinib, entrectinib, repotrectinib, or taletrectinib).

Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.

*At least a 30% decrease as measured by RECIST during 2 different tumor evaluations.
†A complete response (tumor disappearing) does not mean the cancer has been cured.

IMPORTANT SAFETY INFORMATION (cont.)

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you: (cont.)

- are breastfeeding or plan to breastfeed. It is not known if JIDEYTRO passes into your breast milk. **Do not** breastfeed during treatment and for 1 week after your last dose of JIDEYTRO. Talk to your healthcare provider about the best way to feed your baby during treatment with JIDEYTRO.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

INDICATION and IMPORTANT SAFETY INFORMATION

Jideytro™ (zidesamtinib) | 25 mg 100 mg tablets

What is JIDEYTRO™ (zidesamtinib)?

JIDEYTRO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:

- has spread within the chest or other parts of the body and is caused by an abnormal ROS1 gene, and
- who have received a ROS1 kinase inhibitor.

It is not known if JIDEYTRO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

JIDEYTRO can cause serious side effects, including:



Central nervous system (CNS) effects. Tell your healthcare provider right away if you or your family member taking JIDEYTRO develop any new or worsening CNS symptoms during treatment, including:

- dizziness
- fainting
- walking, balance, or coordination problems
- forgetfulness, confusion, attention or thinking problems
- speaking problems
- seizures
- mood or personality changes, including anxiety, irritability
- depression, including thoughts of suicide or dying
- seeing or hearing things that are not real (hallucinations)

Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening or cause sudden death. Your healthcare provider will do tests before and during your treatment with JIDEYTRO to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with JIDEYTRO.

Lung problems. JIDEYTRO can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough (with or without mucus), or fever.

Please see full Prescribing information and Patient Information for JIDEYTRO.

IMPORTANT SAFETY INFORMATION (cont.)

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

JIDEYTRO can cause serious side effects, including: (cont.)



Bone fractures. JIDEYTRO can increase your risk of bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you develop pain, changes in movement, or bone abnormalities.



Muscle pain, tenderness, and weakness (myalgia). JIDEYTRO can cause myalgia with an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK), which may be a sign of muscle damage. Your healthcare provider will do blood tests to check your CPK blood levels every 2 weeks during the first month, then every 1 to 2 months and as needed if you get unexplained muscle pain, tenderness, or weakness during your treatment with JIDEYTRO. Tell your healthcare provider if you develop any of these symptoms.

Inflammation of the pancreas (pancreatitis). JIDEYTRO may increase enzymes in your blood called amylase and lipase, which may be a sign of pancreatitis. Your healthcare provider will do blood tests to check your pancreatic enzyme blood levels during treatment with JIDEYTRO. Tell your healthcare provider right away if you get any signs and symptoms of pancreatitis, including upper stomach (abdominal) pain that may spread to the back and get worse with eating, weight loss, or nausea.

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you:

- have nervous system (neurological) or psychiatric problems.
- have heart problems, including a condition called long QT syndrome.
- have lung or breathing problems other than lung cancer.
- are pregnant or plan to become pregnant. JIDEYTRO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JIDEYTRO.

  Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with JIDEYTRO. Use effective birth control (contraception) during treatment and for 6 months after the last dose of JIDEYTRO. Talk to your healthcare provider about birth control methods that may be right for you.

  Males with a female partner who are able to become pregnant: Use effective birth control during treatment and for 3 months after the last dose of JIDEYTRO.

Please see full Prescribing information and Patient Information for JIDEYTRO.

IMPORTANT SAFETY INFORMATION (cont.)

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

Before taking JIDEYTRO, tell your healthcare provider about all your medical conditions, including if you: (cont.)

- are breastfeeding or plan to breastfeed. It is not known if JIDEYTRO passes into your breast milk. **Do not** breastfeed during treatment and for 1 week after your last dose of JIDEYTRO. Talk to your healthcare provider about the best way to feed your baby during treatment with JIDEYTRO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking JIDEYTRO with certain other medicines may affect the amount of JIDEYTRO or other medicines in your blood and may cause side effects or affect the way that JIDEYTRO or other medicines work.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while taking JIDEYTRO?

- Do not drive or operate heavy machinery during treatment if you develop side effects that can impact your mental alertness or coordination.

What are the most common side effects of JIDEYTRO?

The most common side effects of JIDEYTRO include:

- swelling (edema)
- numbness or tingling in your arms or legs
- constipation
- tiredness
- shortness of breath

The most common severe abnormal blood test results include increased creatine phosphokinase (CPK), increased triglycerides, decreased white blood cell counts and decreased red blood cell counts.

JIDEYTRO may cause fertility problems in males and females. Talk to your healthcare provider if fertility is a concern for you.

These are not all the possible side effects of JIDEYTRO. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch** or call **1-800-FDA-1088**.

Please see full Prescribing information and Patient Information for JIDEYTRO.


Jideytro™
(zidesamtinib) | 25 mg
100 mg tablets

The safety and side effects of JIDEYTRO were studied in **446 people with *ROS1*+ cancer**

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

Among the 446 were 432 people with *ROS1*+ NSCLC who received at least 1 dose of JIDEYTRO at 100 mg. They received JIDEYTRO once daily until their cancer progressed or they needed to stop treatment. Serious side effects occurred in 22% of these people. Serious side effects occurring in at least 2% of people were pneumonia and shortness of breath.

Most common side effects in 15% or more of people who received JIDEYTRO (out of 446):

Swelling (edema)	Numbness or tingling in arms or legs	Constipation	Tiredness	Shortness of breath
38%	25%	17%	16%	15%

The most common severe abnormal blood test results include increased creatine phosphokinase (CPK), increased triglycerides, decreased white blood cell counts and decreased red blood cell counts.

JIDEYTRO may cause fertility problems in males and females. Talk to your healthcare provider if fertility is a concern for you.

These are not all the possible side effects of JIDEYTRO. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch**, or call **1-800-FDA-1088 (1-800-332-1088)**.

For more information, go to **www.JIDEYTRO.com** or call **1-844-NUVL-111 (1-844-688-5111)**.

Treatment experiences can vary—keep track of any side effects and discuss them with your care team.

IMPORTANT SAFETY INFORMATION (cont.)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Tolerability that may help you stay on therapy

Most side effects did not require people to permanently stop treatment or lower their dose in the JIDEYTRO clinical study

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

2.3% **(10 out of 432 people)** permanently stopped treatment because of side effects.

10% **(43 out of 432 people)** needed their dose reduced because of side effects.

The most common reasons for stopping treatment included pneumonia and pneumonitis.

Treatment experiences can vary—keep track of any side effects and discuss them with your care team.

IMPORTANT SAFETY INFORMATION (cont.)

Taking JIDEYTRO with certain other medicines may affect the amount of JIDEYTRO or other medicines in your blood and may cause side effects or affect the way that JIDEYTRO or other medicines work.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Your medication can coexist with your routine

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

Once-daily dosing

Can be taken with or without food

No sun exposure restrictions included in the full Prescribing Information

How to take JIDEYTRO

Take JIDEYTRO exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking JIDEYTRO unless your healthcare provider tells you to

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with JIDEYTRO if you develop side effects

Take JIDEYTRO at about the same time each day with or without food

Swallow JIDEYTRO tablets whole. Do not split, chew, crush, or dissolve the tablets. Do not take a tablet if it is broken, cracked, or damaged

If you miss a dose of JIDEYTRO take it as soon as possible. If it has been 12 or more hours since you took your last dose, just skip the dose and take it at your next regularly scheduled time

If you vomit at any time after taking JIDEYTRO, do not take another dose. Wait to take your next dose at your regularly scheduled time

IMPORTANT SAFETY INFORMATION (cont.)

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Guiding a path to treatment: Nuvalent Patient Support

We're here to help you understand what to expect with your medication, navigate insurance coverage and costs, and start and stay on JIDEYTRO™ (zidesamtinib) with the following programs:

Patient Assistance Program*

If you do not have insurance, your insurance does not cover JIDEYTRO, or you are concerned about the cost of your medication even with insurance, the Patient Assistance Program may be able to provide your medication at no cost if you meet eligibility requirements.

Quick Start Program*

If you are new to JIDEYTRO and there is a delay in insurance review or coverage, you may be eligible to receive a free, temporary supply of medication while you wait for a coverage decision.

Bridge Program*

If you are already taking JIDEYTRO and your insurance changes, you may be eligible for a free, temporary supply of medication while you wait for new insurance or coverage.

Benefits Verification† and Coverage Information

Our team can help you and your healthcare provider understand insurance coverage for your medication, the steps needed to receive approval from your plan, and what costs you may be responsible for.

Advocacy and Community Groups

Our team can connect you to patient advocacy organizations that offer support and resources for patients and their care partners that may be tailored to your specific needs.

Copay Assistance Program

You could pay as little as $0 for JIDEYTRO if you have commercial insurance. Patients covered by Medicare, Medicaid, or other state/federal plans are not eligible. Maximum benefit per calendar year applies.

Talk to your healthcare provider or visit our website to enroll in the above programs.‡

Enroll in Nuvalent Patient Support
NuvalentPatientSupport.com

*Please see the Patient Assistance Program, Quick Start Program, and Bridge Program terms and conditions.

†Verification of benefits is not a guarantee of payment and does not take the place of written policy information. Healthcare providers should carry out their own benefits investigation as necessary.

‡Please see the Copay Assistance Program terms and conditions.

Nuvalent PATIENT SUPPORT

Patient portrayal.

You are part of a strong ROS1+ NSCLC community

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets

The ROS1ders

www.theros1ders.org
A global community for people living with *ROS1+* cancer, offering peer support, education, advocacy, and referrals to ROS1 specialists

LUNGEVITY
Transforming Lung Cancer

www.lungevity.org
Find survivorship resources, caregiver support, and tools for living with lung cancer

GO2 FOR LUNG CANCER

www.go2.org
Access a support helpline, treatment center directory, and trusted education

IMPORTANT SAFETY INFORMATION (cont.)

What should I avoid while taking JIDEYTRO?

- Do not drive or operate heavy machinery during treatment if you develop side effects that can impact your mental alertness or coordination.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

LCFA
Lung Cancer Foundation of America

www.lcfamerica.org
Learn more about lung cancer research and efforts to improve patient outcomes

LUNG CANCER RESEARCH FOUNDATION®

www.lungcancerresearchfoundation.org
Support and education focused on research and patient empowerment

These organizations are separate from Nuvalent and are not connected to JIDEYTRO. They are listed to provide extra information and support, and they should not replace medical advice from your care team.

IMPORTANT SAFETY INFORMATION (cont.)

What are the most common side effects of JIDEYTRO?

The most common side effects of JIDEYTRO include:

- swelling (edema)
- numbness or tingling in your arms or legs
- constipation
- tiredness
- shortness of breath

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Talk to your doctor about JIDEYTRO

44% (51 out of 117) of people with *ROS1*+ NSCLC responded to JIDEYTRO after 1-4 prior ROS1-targeted therapies

Demonstrated tolerability that may help you stay on therapy*

*2.3% of people with *ROS1*+ NSCLC (10 out of 432) receiving JIDEYTRO in the clinical study permanently stopped treatment due to side effects, and 10% of people (43 out of 432) needed their dose reduced due to side effects.

Safety and side effects were studied in 446 people receiving JIDEYTRO

Serious side effects occurred in 22% of people with *ROS1*+ NSCLC who received JIDEYTRO. Serious side effects occurring in at least 2% of people were pneumonia and shortness of breath

The most common side effects were swelling (edema), numbness or tingling in arms or legs, constipation, tiredness, and shortness of breath

Individual treatment results may vary.
Talk to your doctor to see if JIDEYTRO may be right for you.

Visit **JIDEYTRO.com** for more information and *ROS1*+ NSCLC resources

IMPORTANT SAFETY INFORMATION (cont.)

The most common severe abnormal blood test results include increased creatine phosphokinase (CPK), increased triglycerides, decreased white blood cell counts and decreased red blood cell counts.

Please see full Important Safety Information on pages 12–14 and full Prescribing Information and Patient Information for JIDEYTRO.

Nuvalent

Jideytro™ (zidesamtinib) 25 mg 100 mg tablets